keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer,meta-analysis

keyword
https://www.readbyqxmd.com/read/28317869/genetic-association-between-the-cyclin-dependent-kinase-inhibitor-gene-p27-kip1-polymorphism-rs34330-and-cancer-susceptibility-a-meta-analysis
#1
Xiao-Ke Cheng, Xue-Jun Wang, Xiao-Dong Li, Xue-Qun Ren
The p27 rs34330 (-79C/T) polymorphism has been widely studied for human cancer susceptibility. The current findings, however, still remained controversial. Therefore, we performed the meta-analysis to provide a more accurate result. Eligible studies were identified from PubMed database up to June 2015. The association of p27 rs34330 polymorphism and cancer susceptibility was estimated with odds ratios and corresponding 95% confidence intervals. The meta-analysis was performed with Stata 12. A total of ten studies with 11,214 cases and more than 8,776 controls were included in the meta-analysis (including breast, lung, thyroid, endometrial, and hepatocellular cancer)...
March 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28314991/xpg-genetic-polymorphisms-and-clinical-outcome-of-patients-with-advanced-non-small-cell-lung-cancer-under-platinum-based-treatment-a-meta-analysis-of-12-studies
#2
Tianxin Xiang, Xiuhua Kang, Zhenghua Gong, Wei Bai, Chuanhui Chen, Wei Zhang
PURPOSE: A number of studies on the relationship between xeroderma pigmentosum group G (XPG) polymorphisms and clinical outcomes in non-small cell cancer (NSCLC) have led to inconclusive results. This meta-analysis evaluates the predictive value of XPG polymorphisms on the treatment response rate and overall survival of patients with NSCLC. METHODS: To measure the correlative strength of the relationship between XPG polymorphisms and outcomes of patients with NSCLC, we searched electronic databases, including PubMed and China National Knowledge Infrastructure, to retrieve studies up to August 2016...
March 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28301870/the-impact-of-vitamin-d-pathway-genetic-variation-and-circulating-25-hydroxyvitamin-d-on-cancer-outcome-systematic-review-and-meta-analysis
#3
P G Vaughan-Shaw, F O'Sullivan, S M Farrington, E Theodoratou, H Campbell, M G Dunlop, L Zgaga
BACKGROUND: Vitamin D has been linked with improved cancer outcome. This systematic review and meta-analysis investigates the relationship between cancer outcomes and both vitamin D-related genetic variation and circulating 25-hydroxyvitamin D (25OHD) concentration. METHODS: A systematic review and meta-analysis of papers until November 2016 on PubMed, EMBASE and Web of Science pertaining to association between circulating vitamin D level, functionally relevant vitamin D receptor genetic variants and variants within vitamin D pathway genes and cancer survival or disease progression was performed...
March 16, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28295308/comparison-of-gefitinib-erlotinib-and-afatinib-in-non-small-cell-lung-cancer-a-meta-analysis
#4
Zuyao Yang, Allan Hackshaw, Qi Feng, Xiaohong Fu, Yuelun Zhang, Chen Mao, Jinling Tang
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lung cancer (NSCLC) with proven efficacy. We undertook a systematic review and meta-analysis to synthesize existing studies with direct comparisons of EGFR TKIs in NSCLC in terms of both efficacy and safety. Eight randomized trials and 82 cohort studies with a total of 17621 patients were included for analysis. Gefitinib and erlotinib demonstrated comparable effects on progression-free survival (hazard ratio [HR], 1...
March 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28294391/a-population-pharmacokinetic-meta-analysis-of-custirsen-an-antisense-oligonucleotide-in-oncology-patients-and-healthy-subjects
#5
Alena Y Edwards, Anna Elgart, Colm Farrell, Ofra Barnett-Griness, Laura Rabinovich-Guilatt, Ofer Spiegelstein
AIMS: Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK) of custirsen in cancer patients and healthy subjects. METHODS: The population PK analysis used custirsen plasma concentrations from five phase 1 studies, one phase 1/2 study, and one phase 3 study in two stages. Cancer patients received multiple doses of custirsen (40-640 mg intravenously over 120 minutes) with chemotherapy; healthy subjects received single or multiple doses (320-640 mg)...
March 11, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28289835/optimization-of-chest-tube-management-to-expedite-rehabilitation-of-lung-cancer-patients-after-video-assisted-thoracic-surgery-a-meta-analysis-and-systematic-review
#6
Bo Deng, Kai Qian, Jing-Hai Zhou, Qun-You Tan, Ru-Wen Wang
BACKGROUND: The aim of this meta-analysis and systematic review of published evidence was to optimize chest tube management for fast-track rehabilitation of lung cancer patients after video-assisted thoracic surgery (VATS). METHODS: The PubMed, Web of Science, and EMBASE databases were searched to identify all studies that addressed the issue of chest tube management after VATS for lung cancer. Finally, 35 articles were included for analysis, i.e., 29 randomized controlled trials and 6 clinical trials...
March 13, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28288025/coffee-and-cancer-risk-a-summary-overview
#7
Gianfranco Alicandro, Alessandra Tavani, Carlo La Vecchia
We reviewed available evidence on coffee drinking and the risk of all cancers and selected cancers updated to May 2016. Coffee consumption is not associated with overall cancer risk. A meta-analysis reported a pooled relative risk (RR) for an increment of 1 cup of coffee/day of 1.00 [95% confidence interval (CI): 0.99-1.01] for all cancers. Coffee drinking is associated with a reduced risk of liver cancer. A meta-analysis of cohort studies found an RR for an increment of consumption of 1 cup/day of 0.85 (95% CI: 0...
March 10, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28285696/effects-of-aspirin-on-small-cell-lung-cancer-mortality-and-metastatic-presentation
#8
Paul Maddison
Although meta-analysis data have shown that taking regular aspirin may reduce lung cancer mortality, individual trial data results are conflicting, and the data on the effects of aspirin on different histological subtypes of lung tumours, in particular small-cell lung cancer, are sparse. We conducted a prospective observational study of 313 patients with a new diagnosis of small-cell lung cancer and recorded use of aspirin before and after tumour diagnosis. Seventy-one (23%) patients were taking regular daily aspirin for more than 2 years at the time of tumour diagnosis...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28284494/positron-emission-tomography-and-computed-tomographic-imaging-pet-ct-for-dose-planning-purposes-of-thoracic-radiation-with-curative-intent-in-lung-cancer-patients-a-systematic-review-and-meta-analysis
#9
Andreas Hallqvist, Charlotte Alverbratt, Annika Strandell, Ola Samuelsson, Emil Björkander, Ann Liljegren, Per Albertsson
BACKGROUND AND PURPOSE: PET/CT is a proposed management to improve the accuracy of high dose radiochemotherapy in lung cancer patients. This systematic review was performed to investigate the possible impact on clinical outcome and to quantify the effect on patient selection and target definition. MATERIAL AND METHODS: Systematic literature searches were conducted, eligible full-text articles were assessed for quality and data were extracted. RESULTS: Thirty-five cross-sectional studies and one observational study fulfilled the inclusion criteria...
March 8, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28280862/-pulmonary-metastasectomy-in-renal-cell-carcinoma
#10
S Macherey, C Kauffmann, A Heidenreich, F Doerr, T Wahlers, K Hekmat
BACKGROUND: In patients with isolated meta- or synchronous pulmonary metastases from renal cell cancer, lung metastasectomy could be an appropriate treatment option after successful treatment of primary cancer. OBJECTIVES: Presentation of lung metastasectomy as a treatment option in patients with pulmonary metastatic renal cell cancer and the postoperative outcome. Description of alternative treatment modalities focusing on "targeted therapies". MATERIALS AND METHODS: Systematical literature research and qualitative analysis of studies on patients undergoing lung metastasectomy after primary nephrectomy published since 01 January 2000...
March 9, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28280362/sequential-treatment-of-tyrosine-kinase-inhibitor-and-platinum-based-doublet-chemotherapy-on-egfr-mutant-non-small-cell-lung-cancer-a-meta-analysis-of-randomized-controlled-clinical-trials
#11
Lifen Qiao, Jin Wang, Guoxian Long, Yueqiang Jiang
There is debate surrounding which treatment is superior in overall survival (OS) rates in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC); first-line tyrosine kinase inhibitor (TKI) followed by second-line platinum-based doublet chemotherapy (PCT), or the reverse sequence. Cross treatment of first- and second-line TKI and PCT makes it difficult to deduce which sequence (TKI-PCT or PCT-TKI) is better for OS. Using the keywords "lung cancer" and "EGFR" we identified clinical trials within the PubMed database which were published between January 2006 and November 2016...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28278517/carcinoembryonic-antigen-and-cytokeratin-19-fragments-for-assessment-of-therapy-response-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#12
Stefan Holdenrieder, Birgit Wehnl, Karina Hettwer, Kirsten Simon, Steffen Uhlig, Farshid Dayyani
BACKGROUND: This meta-analysis evaluated whether pretherapy serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) are predictive of response to therapy in non-small cell lung cancer (NSCLC) and whether changes in these markers during vs pretherapy are indicative of response. METHODS: Original peer-reviewed studies enrolling adults with untreated advanced NSCLC were identified using PubMed. Two reviewers independently extracted data from eligible studies and assessed study heterogeneity and the risk of study bias...
March 9, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28277871/meta-analysis-of-pemetrexed-plus-carboplatin-doublet-safety-profile-in-first-line-non-squamous-non-small-cell-lung-cancer-studies
#13
Isamu Okamoto, Wolfgang H W Schuette, Thomas E Stinchcombe, José Rodrigues-Pereira, Belén San Antonio, Jian Chen, Jingyi Liu, William J John, Ralph G Zinner
OBJECTIVES: This meta-analysis compared safety profiles (selected drug-related treatment-emergent adverse events [TEAEs]) of first-line pemetrexed plus carboplatin (PCb) area under the concentration-time curve 5 mg/min•mL (PCb5) or 6 mg/min•mL (PCb6), two widely used regimens in clinical practice for advanced non-squamous non-small cell lung cancer. METHODS: All patients received pemetrexed 500 mg/m(2) every 21 days with either of two carboplatin doses for up to 4-6 cycles...
March 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28275479/should-aggressive-thoracic-therapy-be-performed-in-patients-with-synchronous-oligometastatic-non-small-cell-lung-cancer-a-meta-analysis
#14
Dianhe Li, Xiaoxia Zhu, Haofei Wang, Min Qiu, Na Li
BACKGROUND: We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not. METHODS: A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease...
February 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28275115/safety-and-tolerability-of-pd-1-pd-l1-inhibitors-compared-with-chemotherapy-in-patients-with-advanced-cancer-a-meta-analysis
#15
Tomohiro F Nishijima, Shlomit S Shachar, Kirsten A Nyrop, Hyman B Muss
BACKGROUND: Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conducted a systematic review and meta-analysis to compare safety and tolerability between PD-1/PD-L1 inhibitors and chemotherapy. METHODS: PubMed and American Society of Clinical Oncology (ASCO) databases were searched 1966 to September 2016...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28273134/gene-set-meta-analysis-of-lung-cancer-identifies-pathway-related-to-systemic-lupus-erythematosus
#16
Albert Rosenberger, Melanie Sohns, Stefanie Friedrichs, Rayjean J Hung, Gord Fehringer, John McLaughlin, Christopher I Amos, Paul Brennan, Angela Risch, Irene Brüske, Neil E Caporaso, Maria Teresa Landi, David C Christiani, Yongyue Wei, Heike Bickeböller
INTRODUCTION: Gene-set analysis (GSA) is an approach using the results of single-marker genome-wide association studies when investigating pathways as a whole with respect to the genetic basis of a disease. METHODS: We performed a meta-analysis of seven GSAs for lung cancer, applying the method META-GSA. Overall, the information taken from 11,365 cases and 22,505 controls from within the TRICL/ILCCO consortia was used to investigate a total of 234 pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database...
2017: PloS One
https://www.readbyqxmd.com/read/28272463/pd-1-inhibitors-increase-the-incidence-and-risk-of-pneumonitis-in-cancer-patients-in-a-dose-independent-manner-a-meta-analysis
#17
Jiaying Wu, Dongsheng Hong, Xiangnan Zhang, Xiaoyang Lu, Jing Miao
Therapies that targeted PD-1 have shown remarkable rates of durable clinical responses in patients with various tumor types. However, the extent and knowledge of pulmonary toxicities associated with PD-1 blockade, mainly manifested as pneumonitis, remains obscure. In this study, a total of 6360 subjects from 16 phase II/III clinical trials were pooled for meta-analysis to evaluate the overall incidence and risk of PD-1 inhibitors-related pneumonitis in cancer patients. The incidence of pneumonitis during anti-PD-1 immunotherapy was 2...
March 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28266166/prognositc-significance-of-suvmax-on-pretreatment-18-f-fdg-pet-ct-in-early-stage-non-small-cell-lung-cancer-treated-with-stereotactic-body-radiotherapy-a-meta-analysis
#18
Min Dong, Jing Liu, Xiaorong Sun, Ligang Xing
INTRODUCTION: The prognostic importance of the (18) F-FDG PET maximum standardized uptake value (SUVmax ) for early stage non-small cell lung cancer (NSCLC) patients receiving stereotactic body radiotherapy (SBRT) is not well defined. The purpose of this meta-analysis is to evaluate the efficacy of SUVmax on pretreatment (18) F-FDG PET imaging to predict prognosis after SBRT. METHODS: All published English-language studies that assessed the treatment response after SBRT in patients with early-stage NSCLC using (18) F-FDG PET were collected from the EMBASE and MEDLINE databases...
March 7, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28263037/loss-of-phosphatase-and-tensin-homolog-expression-correlates-with-clinicopathological-features-of-non-small-cell-lung-cancer-patients-and-its-impact-on-survival-a-systematic-review-and-meta-analysis
#19
Yongsheng Zhao, Renyan Zheng, Jian Li, Feng Lin, Lunxu Liu
BACKGROUND: Phosphatase and tensin homolog ( PTEN ), regarded as a tumor suppressor gene, may act as a prognostic biomarker in human cancers. METHODS: All eligible studies from MEDLINE, Embase, CENTRAL, and the Chinese BioMedical Literature Database to October 2016 were incorporated. Two reviewers independently screened the literature according to inclusion and exclusion criteria, extracted the data, assessed the methodological quality of the included studies, and conducted meta-analysis...
March 6, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28263036/comparing-the-adverse-effects-of-platinum-in-combination-with-etoposide-or-irinotecan-in-previously-untreated-small-cell-lung-cancer-patients-with-extensive-disease-a-network-meta-analyses
#20
Yujie Chen, Lingxiao Chen, Diansheng Zhong
BACKGROUND: The safety of front-line chemotherapies for the treatment of extensive stage small-cell lung cancer (ED-SCLC) is uncertain. We carried out a network meta-analysis to compare the toxicity of different therapies for ED-SCLC. METHODS: We searched EMBASE, PubMed, CENTRAL and clinicaltrials.gov. We performed network meta-analysis on hematological (anemia, leukopenia, neutropenia, and thrombocytopenia) and non-hematological toxicities (diarrhea, infection, and nausea and vomiting)...
March 6, 2017: Thoracic Cancer
keyword
keyword
15077
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"